A chemically gated platform for precise control of viral gene expression in spinal cord injury

Active Grant Awarded

Award ID
RNS153618UJNBM7
Recipient
Awarding agency
Obligated
$231,750

Award facts

Completion date 0% complete
Place of performance
Wisconsin, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, through the National Institutes of Health's National Institute of Neurological Disorders and Stroke, awarded Marquette University a grant obligating $231,750 on November 19, 2026, under the Neurosciences and Neurological Disorders – Research Projects (RP) program, CFDA 93.NS1. The program supports extramural NINDS research. This award funds development and validation of a dual-compound gene regulation system that controls AAV-delivered transgene expression in the adult central nervous system by gating expression at two levels: ligand-dependent transcriptional activation and independent control of protein stability. The project has three stated aims: optimize compound stability and pharmacokinetics; define induction and washout kinetics in the adult mouse CNS using an inducible fluorescent reporter; and apply the system to reversibly activate a pro-regenerative signaling pathway in corticospinal tract neurons after spinal cord injury. The ultimate completion date is November 30, 2028, and the place of performance is Wisconsin, USA.

Description

Abstract
Gene therapy offers unprecedented opportunities to treat disorders of the central nervous system (CNS) by enabling precise molecular manipulation of defined neuronal populations. However, a major barrier to broader application is the limited ability to tightly control the timing and magnitude of transgene expression once a viral vector has been delivered. This limitation is of particular concern in the context of axon regeneration, where sustained activation of pro-growth pathways can produce deleterious effects, including aberrant circuit function or oncogenic signaling. Thus, there is a critical need for gene regulation platforms that provide extremely low baseline expression, strong induction, and reliable reversibility in vivo. This project will develop and validate a dual-compound system for gene regulation that achieves stringent control of AAV-delivered transgenes in the adult CNS. The platform combines ligand-dependent transcriptional activation with independent control of protein stability, thereby gating expression at two levels to minimize background activity while enabling a wide dynamic range. Preliminary data demonstrate negligible leak in cell-based assays, rapid brain penetration of the activating ligands, and feasibility of engineering stabilized derivatives to enhance in vivo performance. The proposed studies will (1) optimize compound stability and pharmacokinetics, (2) define induction and washout kinetics in the adult mouse CNS using an inducible fluorescent reporter, and (3) apply the system to reversibly activate a pro-regenerative signaling pathway in corticospinal tract neurons after spinal cord injury. Successful completion of this work will establish a broadly applicable platform for precise, reversible gene control in the CNS and establish its utility for reversible activation of pro-regenerative signaling.

Quick answers

Who received award RNS153618UJNBM7?

RNS153618UJNBM7 was awarded to Marquette University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on November 19, 2026.

How much is award RNS153618UJNBM7 worth?

$231,750 has been obligated on RNS153618UJNBM7.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award